List of Excipients in Branded Drug LODINE

✉ Email this page to a colleague

Generic Drugs Containing LODINE

Subscribe to access the full database, or Start Trial
Company	Ingredient	NDC	Excipient
Sallus Laboratories LLC	etodolac	69036-503	CELLULOSE, MICROCRYSTALLINE
Sallus Laboratories LLC	etodolac	69036-503	FERRIC OXIDE RED
Sallus Laboratories LLC	etodolac	69036-503	FERRIC OXIDE YELLOW
Sallus Laboratories LLC	etodolac	69036-503	HYPROMELLOSE 2208
Sallus Laboratories LLC	etodolac	69036-503	LACTOSE MONOHYDRATE
Sallus Laboratories LLC	etodolac	69036-503	MAGNESIUM STEARATE
Sallus Laboratories LLC	etodolac	69036-503	POLYETHYLENE GLYCOLS
>Company	>Ingredient	>NDC	>Excipient

What are the Most Frequently-Used Excipients in LODINE?

Subscribe to access the full database, or Start Trial
# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW
1	HYPROMELLOSE 2208
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOLS
># Of NDCs	>Excipient

Lodine (Etodolac) Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Lodine is the former U.S. brand for etodolac, a nonsteroidal anti-inflammatory drug (NSAID) used for osteoarthritis and rheumatoid arthritis. Its core commercial opportunity is no longer branded exclusivity. The opportunity is in low-cost generic supply, differentiated modified-release products, patient-tolerability positioning, and formulation improvements that address etodolac’s solubility, dose size, and gastrointestinal-risk profile.

Etodolac is an established small-molecule active ingredient with no biosimilar pathway. U.S. generic products can be developed through the abbreviated new drug application (ANDA) route, subject to bioequivalence and applicable labeling requirements. The historical Lodine and Lodine XL patent estate does not present a meaningful current barrier to conventional generic entry.

What is Lodine and which etodolac products were marketed?

Lodine is etodolac, an orally administered NSAID. The product was marketed in immediate-release and extended-release forms.

Product	Active ingredient	Dosage form	Historical strength range	Primary development issue
Lodine	Etodolac	Immediate-release tablet/capsule	Commonly 200 mg, 300 mg, 400 mg	Rapid dissolution, GI tolerability, tablet size
Lodine XL	Etodolac	Extended-release tablet	Commonly 400 mg, 500 mg, 600 mg	Controlled release, food effect, dose dumping
Generic etodolac	Etodolac	Tablet, capsule, extended-release tablet	Multiple strengths	ANDA bioequivalence and manufacturing cost

Etodolac is used at total daily doses that can require multiple immediate-release units. That creates a commercial opening for once-daily or twice-daily modified-release products, provided the formulation meets pharmacokinetic and dissolution requirements.

FDA labeling for etodolac identifies conventional NSAID risks, including gastrointestinal bleeding, cardiovascular events, renal toxicity, and hypersensitivity reactions. Excipient selection cannot eliminate those active-ingredient risks, but it can influence tablet robustness, disintegration, dissolution, dose uniformity, and patient acceptability (U.S. Food and Drug Administration [FDA], 2024a).

What excipients are relevant to Lodine and etodolac formulations?

The highest-value excipient decisions concern solubility enhancement, immediate-release performance, controlled release, manufacturability, and impurity control.

Immediate-release etodolac tablets

A conventional immediate-release formulation can use the following excipient classes:

Function	Candidate excipient classes	Commercial rationale
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet size, flow, and compressibility
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Sodium starch glycolate, croscarmellose sodium, crospovidone	Supports rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports ejection and manufacturing speed
Wetting agent	Sodium lauryl sulfate, poloxamer, surfactant systems	Can improve dissolution of a poorly wetting drug
Film former	Hypromellose, polyvinyl alcohol	Supports swallowability, appearance, and moisture protection

Etodolac has limited aqueous solubility relative to highly soluble drug substances. A formulation that disintegrates rapidly may still show incomplete or variable dissolution if the drug remains poorly wetted. A surfactant, micronized active ingredient, wet granulation process, or solid-dispersion approach can address that problem.

For a standard generic, the commercial target is usually the lowest-complexity formulation that matches the reference product’s dissolution profile and pharmacokinetic exposure. Excessive formulation innovation can increase development cost without creating meaningful market differentiation.

Extended-release etodolac tablets

Lodine XL-type products require a controlled-release matrix or reservoir system. Relevant excipients include:

Hypromellose or other hydrophilic matrix polymers
Ethylcellulose or other water-insoluble release-controlling polymers
Polyethylene oxide
Povidone or copovidone as matrix modifiers
Film-coating polymers
Plasticizers and anti-tacking agents
pH modifiers where justified by dissolution behavior

Hydrophilic matrices are attractive because they can be manufactured with direct compression or wet granulation and can support once-daily dosing. The principal technical risks are dose dumping, sensitivity to alcohol, food-dependent release, and release-rate changes caused by tablet hardness or polymer grade.

A robust extended-release product should be evaluated across:

Multiple dissolution media and agitation speeds.
Fed and fasted conditions.
Alcohol challenge conditions where relevant.
Different tablet hardness ranges.
Storage humidity and temperature conditions.
Strength proportionality across the product line.

The formulation should also control the initial release phase. Excessively rapid early release can undermine the intended pharmacokinetic profile and increase peak-related adverse-event exposure.

What formulation strategy offers the best commercial opportunity?

The strongest strategy depends on the target market.

Low-cost immediate-release generic

The lowest-risk product is an immediate-release tablet using widely available excipients and a conventional manufacturing process. A practical design would combine:

Microcrystalline cellulose or lactose as the principal diluent.
Povidone or copovidone as binder.
Crospovidone or croscarmellose sodium as disintegrant.
Colloidal silicon dioxide as glidant.
Magnesium stearate or sodium stearyl fumarate as lubricant.
A thin film coat for handling and swallowability.

This product competes primarily on price, supply reliability, packaging, and wholesaler access. Because the active ingredient and dosage form are mature, formulation patents are unlikely to support a durable premium unless the product solves a clear technical problem.

Solubility-enhanced immediate-release product

A more differentiated formulation could use micronized etodolac, surfactant-assisted granulation, or a spray-dried dispersion. The commercial advantages may include faster dissolution and reduced variability under low-fluid gastrointestinal conditions.

The disadvantages are material:

Higher process complexity.
Greater control burden for particle size or amorphous content.
Potential physical instability.
More difficult scale-up.
Greater risk that the product will require comparative clinical or pharmacokinetic work beyond a simple conventional formulation.

This approach is more suitable for a 505(b)(2) product or a non-U.S. differentiated product than for a commodity ANDA unless the reference product itself requires a challenging dissolution match.

Extended-release or once-daily product

A once-daily product is the clearest opportunity for product differentiation. It can reduce pill burden and improve adherence for chronic osteoarthritis or rheumatoid arthritis treatment.

The product must compete with:

Generic immediate-release etodolac.
Generic extended-release etodolac.
Other once-daily NSAIDs.
Selective COX-2 inhibitors.
Non-oral and topical pain products.

A once-daily claim has limited value if the product does not improve tolerability, adherence, or total treatment cost. The development program should therefore focus on release consistency, dose flexibility, and a clean food-effect profile rather than simply reproducing a historical extended-release design.

What FDA regulatory pathway applies to Lodine generic products?

Immediate-release products

An immediate-release generic etodolac tablet or capsule would generally use the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must establish pharmaceutical equivalence and bioequivalence to the applicable reference listed drug.

Key requirements include:

Same active ingredient.
Same dosage form and strength.
Equivalent route of administration.
Comparable labeling, subject to permitted generic differences.
Demonstrated bioequivalence.
Acceptable chemistry, manufacturing, and controls information.
Facility compliance with current good manufacturing practice.

FDA’s product-specific guidance and current Orange Book reference listed drug designations determine the practical submission strategy (FDA, 2024b; FDA, 2024c).

Extended-release products

Extended-release etodolac products face more demanding equivalence work. The sponsor must demonstrate that the formulation does not produce clinically meaningful differences in exposure or release behavior.

The principal regulatory issues are:

Partial area under the curve.
Peak concentration.
Total area under the curve.
Fed-versus-fasted pharmacokinetics.
Multiple-strength proportionality.
In vitro dissolution matching.
Alcohol-induced release acceleration.
Strength selection for pivotal bioequivalence testing.

A modified-release formulation with a new release mechanism may qualify for a 505(b)(2) application rather than a conventional ANDA, depending on the reference product and the extent of formulation or labeling differences.

What is the Orange Book status of Lodine?

Lodine is a legacy product. The original brand product is not protected by a current period of new chemical entity exclusivity, orphan exclusivity, pediatric exclusivity, or other meaningful market exclusivity.

The principal commercial conclusion is:

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired
Orphan exclusivity	Not applicable
Pediatric exclusivity	Expired or not commercially relevant
Original formulation patents	Expired
Immediate-release generic entry	Generally open, subject to current reference-product status
Extended-release generic entry	Open in principle, with higher bioequivalence complexity
Biosimilar competition	Not applicable

Orange Book status must be checked by product number and dosage form because the regulatory reference product, discontinued status, and listed patents can differ among immediate-release and extended-release products. The historical Lodine estate should not be treated as a current blocking position without a live Orange Book review and a claim-by-claim patent search (FDA, 2024c).

When did Lodine lose exclusivity and when can generics enter?

Lodine lost meaningful U.S. exclusivity many years ago. Etodolac was approved in the 1980s, and generic versions have been marketed for decades. Any original composition, formulation, or method-of-use patents associated with the brand’s initial launch period have passed their ordinary statutory terms.

Generic entry is therefore governed mainly by:

FDA approval status.
Availability of a reference listed drug.
Bioequivalence requirements.
Current manufacturing compliance.
Commercial supply economics.
Any later-listed patents covering a specific formulation or use.

For immediate-release etodolac, the market is mature and price-sensitive. For extended-release products, technical development and limited market size can be more important barriers than patent rights.

What patent protection covers etodolac formulations?

The relevant patent categories are:

Composition-of-matter patents for etodolac.
Immediate-release formulation patents.
Extended-release matrix or coating patents.
Particle-size, solid-state, or dissolution-enhancement patents.
Method-of-use patents for pain, osteoarthritis, or rheumatoid arthritis.
Manufacturing-process patents.

The composition-of-matter position is no longer commercially relevant in the United States. Broad method-of-use claims are also unlikely to block generic treatment of approved indications because generic labeling ordinarily follows the approved reference labeling.

The most commercially relevant potential patent strategy for a new entrant would involve a narrow formulation claim, such as:

A defined polymer ratio.
A specified dissolution profile.
A particle-size distribution.
A low-impurity manufacturing process.
A once-daily pharmacokinetic profile.
A formulation with reduced food effect.

Such claims would need credible technical differentiation and must survive written-description, enablement, novelty, obviousness, and infringement scrutiny. A formulation patent with no demonstrated clinical or manufacturing advantage has limited licensing value.

Are Paragraph IV challenges likely for Lodine?

Paragraph IV litigation risk is low for conventional etodolac because the original product is old and generic competition is already established. A Paragraph IV filing could arise against a later-listed patent covering a new extended-release product, delivery system, or differentiated formulation.

The practical risk differs by product:

Product type	Paragraph IV risk	Main issue
Conventional immediate-release tablet	Low	Mature, commoditized product
Conventional capsule	Low	Limited differentiation
Extended-release tablet	Moderate	Release-control claims may be listed
Solubility-enhanced formulation	Moderate	Particle-size or solid-state patents
New indication or combination product	Higher	Later patent estate may be active

A generic applicant should perform a current patent-certification review before filing. Patent risk should be assessed against the exact reference listed drug, strength, dosage form, and proposed labeling rather than against the Lodine name generally.

How strong is the Lodine patent estate?

The legacy Lodine patent estate is weak as a current commercial barrier. Its principal value is historical rather than exclusionary.

Estate component	Assessment
Active ingredient	No current blocking value
Immediate-release formulation	Low blocking value
Extended-release formulation	Potentially relevant only to specific later products
Method of use	Limited blocking value because approved NSAID uses are mature
Manufacturing process	Potential value only if current and difficult to design around
Trade dress and brand	No generic-entry blocking effect
Regulatory exclusivity	No meaningful current protection

Patent strength for a new etodolac product would depend on claim scope and technical evidence. A narrow extended-release patent may have greater practical value than a broad but vulnerable excipient claim if the release profile is difficult to reproduce.

What commercial opportunities exist for etodolac?

Generic supply and contract manufacturing

The largest opportunity is dependable low-cost supply. Buyers may value:

Dual-source active pharmaceutical ingredient supply.
Domestic or regional finished-dose manufacturing.
Short lead times.
Multiple bottle and blister configurations.
Stable supply for institutional contracts.
Low-defect, high-throughput tableting.

Because etodolac is an established generic, manufacturing efficiency can matter more than novel excipient technology.

Modified-release products

A once-daily product may support a higher margin if it achieves:

Consistent 24-hour exposure.
Low food sensitivity.
No alcohol-induced dose dumping.
Acceptable tablet size.
Multiple strengths.
A simple administration schedule.

Commercial success depends on payer placement and physician acceptance. The product must justify any price premium against inexpensive immediate-release etodolac and competing NSAIDs.

Patient-centered formulations

Potential differentiated products include:

Smaller tablets.
Film-coated units with improved swallowability.
Blister packaging for adherence.
Lower tablet burden through higher-strength units.
Suspension or sprinkle-compatible dosage forms, if technically and regulatorily justified.
Products designed for patients with swallowing difficulty.

A liquid or dispersible product would require careful control of taste, physical stability, dosing accuracy, and preservative performance. It may address a niche market but would not automatically create broad commercial demand.

Non-U.S. markets

Etodolac is marketed in multiple countries, but regulatory status, approved strengths, reference products, and patent positions vary by jurisdiction. Opportunities may exist in markets where:

Etodolac remains prescribed for chronic musculoskeletal conditions.
Extended-release products have limited competition.
Local manufacturing receives procurement preference.
Patients need lower-cost alternatives to other NSAIDs.

Geographic expansion requires separate review of local registration pathways, excipient acceptability, trademark rights, data requirements, and pharmacovigilance obligations.

What licensing and partnership opportunities exist?

There is little reason to license the legacy Lodine brand for ordinary generic entry. The more credible partnership opportunities are:

Etodolac active-ingredient supply agreements.
Contract development of extended-release tablets.
Co-development of a 505(b)(2) modified-release product.
Regional licensing of a differentiated dosage form.
Manufacturing technology transfer for high-throughput tableting.
Distribution partnerships in markets with limited generic supply.

A licensor would need to offer more than an old brand name. Valuable assets could include a current formulation patent, validated bioequivalence package, manufacturing know-how, regulatory approvals, or established institutional contracts.

What are the main formulation and manufacturing barriers?

The principal technical barriers are manageable but material:

Etodolac dissolution may be sensitive to particle size, wetting, and granulation conditions.
Lubricant overuse can slow dissolution.
Extended-release products can show release variability after scale-up.
Hydrophilic matrices can change performance with polymer grade and compression force.
High-dose tablets can create size and swallowability problems.
Moisture can affect granule properties, tablet hardness, and dissolution.
Surfactants can improve wetting but may complicate stability and tolerability.
Coating defects can alter handling and release performance.
Generic substitution depends on exact reference-product requirements.
NSAID labeling and risk management limit claims that imply improved safety without supporting evidence.

Process analytical technology should monitor blend uniformity, granule moisture, tablet weight, hardness, friability, coating weight gain, and dissolution. For extended-release products, dissolution should be treated as a critical quality attribute rather than a release-test formality.

How does Lodine compare with other NSAID opportunities?

Etodolac has a mature market and limited intellectual-property protection. Compared with newer NSAIDs, it offers lower development risk but also lower pricing power.

Opportunity	Patent barrier	Formulation opportunity	Commercial profile
Generic etodolac IR	Low	Low to moderate	High price pressure
Generic etodolac ER	Low to moderate	High	Smaller market, better differentiation
Celecoxib generic	Low	Moderate	Larger competitive field
Meloxicam generic	Low	Moderate	Strong generic competition
Novel NSAID delivery system	Variable	High	Higher development and regulatory cost
Etodolac 505(b)(2) product	Variable	High	Potential premium if clinically differentiated

The best risk-adjusted opportunity is usually a conventional generic with efficient production. The best higher-margin opportunity is an extended-release or patient-centered dosage form supported by defensible formulation know-how.

Key Takeaways

Lodine is the former U.S. brand for etodolac.
Original Lodine exclusivity and patent protection have expired.
Immediate-release generic entry is a mature, low-barrier opportunity with substantial price pressure.
The principal formulation challenge is achieving reliable dissolution while controlling tablet size and manufacturability.
Extended-release etodolac offers greater differentiation but requires stronger pharmacokinetic, dissolution, food-effect, and dose-dumping controls.
The most commercially valuable new IP would likely concern a technically differentiated release profile, particle-size system, or manufacturing process.
A conventional generic would generally use the ANDA pathway; a substantially differentiated product may require a 505(b)(2) strategy.
Biosimilar competition is irrelevant because etodolac is a small-molecule drug.
Licensing value lies in current formulation technology, regulatory approvals, manufacturing capability, and distribution access, not in the historical Lodine brand alone.
Current Orange Book and patent records should be reviewed by exact dosage form and reference product before launch or filing decisions.

FAQs About Lodine Excipient Strategy and Commercialization

Can etodolac be reformulated as an over-the-counter product?

Etodolac is generally positioned as a prescription NSAID in the United States. An over-the-counter switch would require FDA review of safety, labeling, consumer comprehension, dose selection, and unsupervised-use risks. It is not a routine generic reformulation opportunity.

Which excipient is most important for etodolac dissolution?

No single excipient determines performance. Wetting agents, disintegrants, particle size, granulation method, and lubricant concentration collectively influence dissolution. Surfactant-assisted formulation can help, but it must be balanced against stability and process-control requirements.

Is Lodine XL easier to genericize than immediate-release Lodine?

No. Extended-release etodolac can offer greater commercial differentiation, but it is generally more difficult to genericize because the applicant must match release behavior and pharmacokinetic exposure under multiple conditions.

Can a new etodolac formulation receive patent protection?

Yes, if the formulation has patentable technical characteristics such as a novel release-control system, defined particle-size profile, solid-state form, or manufacturing process. The claims must be sufficiently novel, non-obvious, enabled, and commercially relevant.

Is etodolac a suitable candidate for a 505(b)(2) product?

It can be, particularly for a modified-release, liquid, dispersible, or otherwise differentiated dosage form. The regulatory value depends on the extent of the formulation change and the ability to rely on existing FDA findings for etodolac while providing required bridging data.

References

U.S. Food and Drug Administration. (2024a). Etodolac prescribing information. FDA-approved labeling database.
U.S. Food and Drug Administration. (2024b). Generic drug user fees and abbreviated new drug applications. https://www.fda.gov
U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2024d). Product-specific guidances for generic drug development. https://www.fda.gov
U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
DailyMed. (2024). Etodolac drug labels and inactive ingredient information. National Library of Medicine. https://dailymed.nlm.nih.gov/

More… ↓

⤷ Start Trial